Boswellia does not appear to increase estrogen. The available research actually points in the opposite direction: its active compounds may reduce the activity of estrogen receptors rather than stimulate them. No human study has found that boswellia raises estrogen levels, and cell studies suggest it works against estrogen signaling in certain tissues.
What the Research Shows About Boswellia and Estrogen
The most direct evidence comes from laboratory research on AKBA, one of the primary active compounds in boswellia resin. In precancerous breast cells, AKBA decreased the expression of estrogen receptor alpha, the main receptor through which estrogen drives cell growth. It did this by activating a small RNA molecule that directly targets and suppresses the gene responsible for producing that receptor. In other words, AKBA made the cells less responsive to estrogen, not more.
Network pharmacology analysis (a method of mapping how a compound interacts with biological targets) identified the estrogen receptor gene as AKBA’s highest-scoring target. But “targeting” a receptor doesn’t mean activating it. In this case, the interaction was inhibitory. The same analysis flagged the aromatase gene, which codes for the enzyme that converts testosterone into estrogen. While direct studies on boswellia’s effect on aromatase activity in humans are lacking, the identification of this target suggests boswellia may influence estrogen production pathways without necessarily boosting them.
Boswellia Is Not a Phytoestrogen
Phytoestrogens are plant compounds that mimic estrogen by binding to estrogen receptors and triggering a weak estrogenic response. Soy isoflavones and red clover are classic examples. Boswellia does not fall into this category. Its boswellic acids have a completely different chemical structure, and no research has demonstrated that they activate estrogen receptors the way phytoestrogens do. If you’re avoiding phytoestrogens for a health reason, boswellia is a different class of compound entirely.
Effects on Estrogen-Driven Conditions
Endometriosis, a condition fueled in part by estrogen, provides an indirect window into how boswellia interacts with hormonal tissue. In a rat model of endometriosis, oral boswellia extract reduced both the size and volume of endometriotic lesions. Ultrasound and tissue analysis confirmed that treated animals had smaller growths with less of the characteristic abnormal tissue. The researchers attributed the benefit primarily to boswellia’s antioxidant effects (it boosted the body’s internal antioxidant defenses and reduced a marker of cellular damage) and its ability to promote the natural death of abnormal cells. The study did not find that boswellia worked by lowering estrogen directly, but the fact that it shrank estrogen-dependent tissue is notable.
In a Phase Ia clinical trial, 18 women with breast cancer took 2,400 mg of boswellia daily before surgery for a median of 11 days. All patients in the study had estrogen receptor-positive or progesterone receptor-positive tumors. Boswellia reduced tumor cell proliferation and was well tolerated, with no serious drug-related side effects. Lab work confirmed that boswellia inhibited the growth of both estrogen receptor-positive and triple-negative breast cancer cells in culture. These findings reinforce that boswellia works against, not with, estrogen-driven cell growth.
Effects on Other Hormones
One animal study looked at the broader hormonal impact of boswellia in male rats given the extract daily for 28 days. At the highest dose tested (equivalent to a very large human dose), testosterone levels dropped significantly. Lower and moderate doses did not produce this effect. The researchers noted the testosterone reduction likely involved mechanisms beyond direct damage to the testes, possibly pointing to effects on the hormonal signaling chain. No equivalent study has been done in humans, so it’s unclear whether standard supplement doses would meaningfully affect testosterone or other sex hormones in people.
Safety and Dosing Considerations
The National Center for Complementary and Integrative Health notes that boswellia extract has been safely used in clinical trials at doses up to 1,000 mg daily for as long as six months, and at 2,400 mg daily for up to one month. Side effects in studies are generally mild, mostly limited to digestive discomfort.
If you take hormone replacement therapy or oral contraceptives, there is no specific research on how boswellia interacts with those medications. The NHS advises that herbal supplements in general have not been tested for interactions with HRT the way prescription drugs have. Boswellia is known to interact with blood thinners, certain transport proteins in the liver, and some other drug classes, so it’s worth checking with a pharmacist if you take other medications alongside it.
The breast cancer trial specifically excluded patients already on endocrine therapy, which means we don’t have data on whether boswellia would interfere with or enhance drugs like tamoxifen or aromatase inhibitors. That gap is worth keeping in mind if you’re managing an estrogen-sensitive condition with medication.